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Case Two: Six medications were intervened upon by MTM call
center pharmacists after a patient’s medication history was
reviewed. Speciﬁc interventions accepted by the prescriber
included: combining multiple medications to a single medication
for the purpose of decreasing pill load and discontinuing med-
ication due to duplicate therapy. Assuming all medications were
maintenance medications and the patient would be in full com-
pliance with the recommended medications for the next 12
months, the total pharmacy saving for this case would be $1,019
per year.
Case Three: A patient was identiﬁed as HIV positive through drug
inference and conﬁrmed by the physician. MTM call center phar-
macists recommended adding an NRTI in accordance with
national guidelines. MTM pharmacists also noticed the patient
was noncompliant with his lipid lowering therapy, Tricor, and
recommended promoting proper use of this medication. The total
added drug cost from these recommendations would be $3,695
per year. However, incorporating the NRTI into the drug therapy
could result in $10,000 per year savings in medical cost in accor-
dance with literature. In this particular case, the net savings in
overall health care expenditures could be $6,305 per year.
Overall, the WHS polypharmacy MTMP identiﬁed 359,124
Medicare Part D members eligible for the program in 2006.
However, only about 5% of the qualiﬁed members were enrolled
in the program largely due to the chosen opt-in program design.
The WHS polypharmacy MTMP provided appropriate
therapy recommendations to the patients’ physicians, addressed
compliance and persistency issues, and optimized drug therapy.
Drug therapy outcomes have been improved by ensuring efﬁcacy
and minimizing toxicities through decreasing the number of drug
conﬂicts (e.g. drug interactions, duplicate therapy). According to
literature, clinical outcomes may be improved as a consequence
of this intervention. In addition to bringing better health out-
comes, the WHS polypharmacy MTMP could also reduce both
pharmacy and medical health care expenditures.
Lessons Learned: The WHS Polypharmacy MTMP participation
rates varied by the plan design. Overwhelmingly, those plans
with a polypharmacy MTMP opt-out design had a much higher
patient participation rate in comparison to plans with an opt-in
design (82.26% vs. 4.43%). Possible reasons for the low member
participation rate in the opt-in model include members having
difﬁculties understanding the beneﬁts and opt-in invitations
being discarded with the materials that members did not see as
pertinent.
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Problem or Issue Addressed: Inappropriate use of growth
Hormone.
Goal: The goal of the program was to identify off label use of
growth hormone.
Outcomes items used in the decision: Pharmacy and medical data
with diagnosis was used for identiﬁcation.
Implementation Strategy: Members receiving growth hormone
were identiﬁed by using Pharmacy and medical claims data. The
physicians prescribing these members were also identiﬁed. com-
munications were sent to members and Physicians who did not
meet the FDA approved criteria or the diagnosis. Based on the
responses the next step was either disconitnuation or further
investigation.
Results: We identiﬁed 78 members who received growth hormone
in the ﬁrst quarter of 2006, letters were sent to 35 members who
met the criteria of inappropriate use. This resulted in 28 blocks
and based on that the yearly savings was approx. $400,000. This
also included identifying 17 prescribers who were not using
growth hormone according to FDA approved indication and were
refered to investigation department for reviews.
Conclusions/Lessons Learned: The program was very effective
in identifying a potential problem of inapprpriate utilization and
helped the organization both clinically and ﬁnancially. integra-
tion of pharamcy and medical data provided evidence to take
measures for inappropriate utilization.
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Problem or Issue Addressed: Use of gene testing to guide war-
farin dosing.
Organization: This project is being undertaken at Intermountain
Healthcare, an integrated health care system based in Utah, coor-
dinated by its Clinical Genetics Institute (CGI), in collaboration
with researchers at the University of Washington.
Problem or Issue Addressed: Warfarin is an effective anticoagu-
lant but has signiﬁcant bleeding risk. Recently variants in two
genes, CYP2C9 and VKORC1, have been shown to have a sig-
niﬁcant impact on the pharmacokinetics and pharmacodynam-
ics of warfarin, accounting for signiﬁcant variability in effective
dose between individuals. Though determination of variants of
these genes, when performed in a timely manner, can be incor-
porated into the algorithm used to determine starting dose of
warfarin, it is not clear whether the additional resources required
provide meaningful clinical beneﬁt.
Goals: The CGI hopes to use this project as a pilot to introduce
clinically useful, cost-effective (CE) genetic testing into the Inter-
mountain system, as well as developing methods that can be used
to make coverage decisions by the system’s health plan. The
primary goal is to determine both the clinical and economic value
of adding testing for these genes into the warfarin dosing algo-
rithm, in the setting of a community-based hospital, in order to
inform decisions about the use and coverage of the testing. The
secondary goal is to use this pilot to help educate stakeholders
in the principles of cost effectiveness.
Outcomes items used in the decision: The primary endpoints are
the differences in the total cost of anticoagulation-related care,
the cost per adverse event avoided, and the cost per day within
therapeutic range.
Implementation Strategy: The intent is to use the results from the
cost effectiveness study in conjunction with the results of the clin-
ical trial, to bring the health plan decision makers together with
the delivery-side decision makers to make a coordinated deci-
sion, explicitly including local economic outcomes, about both
the use of and reimbursement for CYP2C9 and VKORC1 testing
in this setting. These efforts will be applied in the context of the
principles of process improvement and clinical decision support,
both integral parts of Intermountain’s culture, to ensure their
consistent and efﬁcient application.
Results: The study is currently underway.
Lessons Learned: Health plans will increasingly be required to
develop coverage and reimbursement policies for genetic tests,
which can present a complex balance of beneﬁts, risks, and costs.
Because sufﬁcient evidence for decision-making may not be avail-
